US Commercial Expansion Leverage the full US market release of CAP24 and EVA sensing technologies to target neurosurgery and orthopedic spine practices across the United States, positioning Saluda Medical as the only FDA-approved closed-loop options with broad deployment.
Launch Momentum Capitalize on recent high-visibility launches and revenue upticks, using the upcoming CAP24 and EVA implementations to build case studies and reference sites that demonstrate improved outcomes and sales traction to potential hospital systems.
Growth Funding Signals Align sales conversations with the company’s strong funding history and IPO-backed expansion to reassure customers of ongoing investment in R&D and service capabilities, while highlighting capacity for scale.
Integrated Tech Stack Position Saluda as a turnkey partner by emphasizing compatibility with common enterprise platforms (Salesforce, Microsoft 365, Jira, VMware) to streamline procurement, training, and post-implant support for hospital IT and clinical teams.
Strategic Partnerships Target strategic neuro/ortho centers and early-adopter hospitals that can serve as flagship sites for CAP24 and EVA deployments, using the company’s closed-loop technology as a differentiator in competitive bids.